Zealand Pharma (22Z) Stock Price & Analysis
22Z Stock Chart & Stats
- Day’s Range
- EUR 30.49 - EUR 31.18
- 52-Week Range
- EUR 29.59 - EUR 73.90
- Previous Close
- EUR 31.57
- Volume
- 20
- Average Volume (3M)
- 402
- Market Cap
- EUR 2.22B
- Enterprise Value
- EUR 6.45B
- Total Cash (Recent Filing)
- EUR 8.54B
- Total Debt (Recent Filing)
- EUR 394.64M
- Price to Earnings (P/E)
- 6.0
- Beta
- 1.48
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- -1.38
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Zealand Pharma News
Zealand Pharma Advances Petrelintide Into Phase III, Raising Its Profile in the Obesity Drug Race
Zealand Pharma A/S ($ZLDPF) announced an update on their ongoing clinical study. Zealand Pharma A/S (ZLDPF) and Hoffmann-La Roche are moving a key obesity drug into late-stage testing. The Phase
Zealand Pharma’s Dasiglucagon Study Moves Forward in Rare Childhood Disease
Zealand Pharma A/S ($ZLDPF) announced an update on their ongoing clinical study. Zealand Pharma’s extension study, officially titled “An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for
22Z FAQ
What was Zealand Pharma’s price range in the past 12 months?
What is Zealand Pharma’s market cap?
When is Zealand Pharma’s upcoming earnings report date?
How were Zealand Pharma’s earnings last quarter?
Is Zealand Pharma overvalued?
Does Zealand Pharma pay dividends?
What is Zealand Pharma’s EPS estimate?
How many shares outstanding does Zealand Pharma have?
What happened to Zealand Pharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Zealand Pharma?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Zealand Pharma
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Adam Sinding Steensberg
- Employees
- 578
- Website
- www.zealandpharma.com
- Address
- Sydmarken 11, Søborg, 2860, DK
Zealand Pharma (22Z) Earnings & Revenues
22Z Company Deck
22Z Earnings Call
Earnings Call SentimentPositive
The call presented a broadly positive view: Zealand Pharma finished 2025 with a strong cash position, a large Roche upfront and a profitable year, multiple high-impact near-term clinical catalysts (petrelintide Phase II readout, survodutide Phase III readouts) and a positive Phase I for ZP9830. Management outlined ambitious Phase III plans and significant R&D expansion supported by partnerships. Offsetting this optimism are meaningful operating expense increases in 2026, revenue dependence on milestone timing and partner execution, and market-level uncertainties around tolerability, persistence and pricing in the obesity space. On balance, the highlights—strong finances, validated partnerships, multiple upcoming data readouts and positive early clinical signals—outweigh the lowlights.
View all DE:22Z earnings summaries22Z Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 1 | 0 | 11 |